Skip to main content
Free access
ORIGINAL REPORTS
August 02, 2010

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Publication: Journal of Clinical Oncology

Authors' Disclosures of Potential Conflicts of Interest

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.
Employment or Leadership Position: Graham Temple, Boehringer Ingelheim (C); Susan Bell, Boehringer Ingelheim (C); Mehdi Shahidi, Boehringer Ingelheim (C); Martina Uttenreuther-Fischer, Boehringer Ingelheim (C); Peter Stopfer, Boehringer Ingelheim (C) Consultant or Advisory Role: James Spicer, Boehringer Ingelheim (C); Johann S. de Bono, Boehringer Ingleheim (C), AstraZeneca (C), OSI Pharmaceuticals (C), Genentech (C), Roche (C) Stock Ownership: None Honoraria: James Spicer, Boehringer Ingelheim; Johann S. de Bono, Boehringer Ingelheim, AstraZeneca Research Funding: None Expert Testimony: None Other Remuneration: None

Information & Authors

Information

Published In

Journal of Clinical Oncology
Pages: 3965 - 3972
PubMed: 20679611

History

Published online: August 02, 2010
Published in print: September 01, 2010

Permissions

Request permissions for this article.

Authors

Affiliations

Timothy A. Yap
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Laura Vidal
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Jan Adam
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Peter Stephens
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
James Spicer
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Heather Shaw
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Jooern Ang
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Graham Temple
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Susan Bell
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Mehdi Shahidi
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Martina Uttenreuther-Fischer
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Peter Stopfer
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Andrew Futreal
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Hilary Calvert
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Johann S. de Bono [email protected]
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Ruth Plummer
From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.

Notes

T.A.Y. and L.V. contributed equally to this work.
Corresponding author: Johann S. de Bono, MB ChB, FRCP, MSc, PhD, Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and the Section of Medicine, The Institute of Cancer Research, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom; e-mail: [email protected].

Author Contributions

Conception and design: Timothy A. Yap, Laura Vidal, Graham Temple, Susan Bell, Mehdi Shahidi, Peter Stopfer, Johann S. de Bono
Administrative support: Graham Temple, Susan Bell
Provision of study materials or patients: Timothy A. Yap, Laura Vidal, Jan Adam, Peter Stephens, James Spicer, Heather Shaw, Jooern Ang, Graham Temple, Susan Bell, Hilary Calvert, Johann S. de Bono, Ruth Plummer
Collection and assembly of data: Timothy A. Yap, Laura Vidal, Graham Temple, Susan Bell, Martina Uttenreuther-Fischer, Peter Stopfer, Andrew Futreal, Johann S. de Bono, Ruth Plummer
Data analysis and interpretation: Timothy A. Yap, Laura Vidal, Mehdi Shahidi, Martina Uttenreuther-Fischer, Peter Stopfer, Andrew Futreal, Johann S. de Bono, Ruth Plummer
Manuscript writing: Timothy A. Yap, Laura Vidal, James Spicer, Jooern Ang, Graham Temple, Susan Bell, Peter Stopfer, Johann S. de Bono, Ruth Plummer
Final approval of manuscript: Timothy A. Yap, Laura Vidal, Jan Adam, Peter Stephens, James Spicer, Heather Shaw, Jooern Ang, Graham Temple, Susan Bell, Mehdi Shahidi, Martina Uttenreuther-Fischer, Peter Stopfer, Andrew Futreal, Hilary Calvert, Johann S. de Bono, Ruth Plummer

Funding Information

Supported by Boehringer Ingelheim; the Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a program grant from Cancer Research UK. Support was also provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer Research) and the National Institute for Health Research Biomedical Research Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research). Northern Institute for Cancer Research, Newcastle University is supported by programmatic grant funding from Cancer Research UK and is an Experimental Cancer Medicine Centre.

Metrics & Citations

Metrics

Altmetric

Citations

Article Citation

Download Citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Timothy A. Yap, Laura Vidal, Jan Adam, Peter Stephens, James Spicer, Heather Shaw, Jooern Ang, Graham Temple, Susan Bell, Mehdi Shahidi, Martina Uttenreuther-Fischer, Peter Stopfer, Andrew Futreal, Hilary Calvert, Johann S. de Bono, Ruth Plummer
Journal of Clinical Oncology 2010 28:25, 3965-3972

View Options

View options

View Full Text HTML

View Full Text HTML

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login

Purchase Options

Purchase this article to get full access to it.

Purchase this Article

Subscribe

Subscribe to this Journal
Renew Your Subscription
Become a Member

Media

Figures

Other

Tables

Share

Share

Share article link

Share